PIP Framework Secretariat

Indicators and milestones

The PIP Secretariat leads, manages and supports implementation of the PIP Framework

Indicator baseline and targets

Table 1. Output indicator baseline and targets

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Baseline (2023 results)</th>
<th>Target as of Dec 2025</th>
<th>Target as of Dec 2027</th>
<th>Target as of Dec 2029</th>
</tr>
</thead>
<tbody>
<tr>
<td>PIP1.1</td>
<td>Proportion of Partnership Contributions received in year of invoice</td>
<td>40%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>PIP1.2</td>
<td>Number of SMTA2s concluded and/or reviewed</td>
<td>0</td>
<td>5</td>
<td>10</td>
</tr>
</tbody>
</table>
## Indicator metadata

<table>
<thead>
<tr>
<th>PIP1.1</th>
<th>Proportion of Partnership Contributions received in year of invoice</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rationale for use</strong></td>
<td>As one element of the PIP Framework’s benefit sharing system, the PIP Secretariat collects $US 28 million in partnership contribution funds annually and relies on the timely receipt of funds for improving influenza pandemic preparedness and response and supporting the functions of the PIP Secretariat.</td>
</tr>
</tbody>
</table>
| **Relevant Output(s)/deliverables** | **Output:** The PIP Secretariat leads, manages and supports implementation of the PIP Framework  
**Deliverable B:** Collect, implement, monitor, and report on the Partnership Contribution |
| **Definition of key terms** | Partnership Contributions: annual voluntary payments made by the influenza vaccine, diagnostic and pharmaceutical manufacturers that use the WHO GISRS, 10% of which are allocated to the PIP Secretariat with the remainder being distributed 30% for response and 70% for preparedness. |
| **Measurement** |  
**Numerator** | Amount of Partnership Contributions received in year of invoice (USD)  
**Denominator** | Annual PC funds of $US 28 million |
| **Disaggregation by** | N/A  
**Data collection and reporting** |  
**Data source/means of verification** | Pandemic Influenza Preparedness Unit  
WHO Finance Department |
| **Period covered** | From 1 January to 31 December |
| **Reporting frequency** | Updated once annually  
(Reported as latest annual status) |
**Indicators and milestones**

**PIP1.2 Number of SMTA2s concluded and/or reviewed**

| Rationale for use | By concluding SMTA2s with non-GISRS entities, WHO secures access to pandemic influenza products and other benefits. In accordance with article 6.2 of the SMTA2, all the agreements with manufacturers (Categories A and B) are to be reviewed at a minimum every 4 years. The purpose of this process is to ensure that the SMTA2s are up to date and ready to be operationalized in the event of an influenza pandemic. |
| Relevant Output(s)/deliverables | Output: The PIP Secretariat leads, manages and supports implementation of the PIP Framework  
Deliverable C: Standard Material Transfer Agreements 2 (SMTA2) are concluded, reviewed, and operationalized |
| Definition of key terms | SMTA2: A Standard Material Transfer Agreement 2 is a legally binding agreement between WHO and a non-GISRS entity that received PIP Biological Materials from GISRS. The entity commits to provide to WHO specific items that may be used to prepare for or respond to pandemic influenza. **Signatories are classified into three different categories.**  
Category A: Vaccine & antivirals manufacturers  
Category B: Diagnostics manufacturers of other products  
Category C: Academic and research institutions and other entities |
| Measurement | Numerator: Number of new SMTA2 concluded, and/or number of Category A and B agreements reviewed  
Denominator: N/A  
Disaggregation by: N/A |
| Data collection and reporting | Data source/means of verification: Pandemic Influenza Preparedness Unit  
Period covered: From 1 January to 31 December  
Reporting frequency: Updated once annually. (Reported as cumulative across 3 biennia of HLIP III) |
## Milestones

### Deliverable A  Promote the effective implementation of the PIP Framework in a changing environment

**Milestones**

- Meetings held and reports submitted to WHO DG or governing bodies to support implementation of Section 7 (Governance and review) of the PIP Framework

**Details for milestone reporting**

- Total number of meetings held and reports submitted

- Documents/reports developed for the World Health Assembly or Executive Board

**Details for milestone reporting**

- Total number and status of documents/reports developed for the World Health Assembly or Executive Board
  - Early scoping/Under discussion
  - In process (draft reports)
  - Final & published

### Deliverable B  Collect, implement, monitor, and report on the Partnership Contribution

**Status in annual project management cycle: Planning**

- Invoices sent by 30 June (Yes/No)
- PC funds distributed by 31 December (Yes/No)

**Implementation: Site monitoring visits conducted**

- Number of site monitoring visits
- Place of visit (Member State). If online, then Virtual
- Date

**Monitoring: Work plan compliance checks conducted**

- Jan - June (Yes/No)
- July - Dec (Yes/No)

**Reporting: PC implementation updates published in newsletter and/or website**

- Number of PC implementation updates published in newsletter and/or website

### Deliverable C  Standard Material Transfer Agreements 2 (SMTA2) are concluded, reviewed, and operationalized

**SMTA2s under negotiation or under review**

- Date of reporting
- Total number of SMTA2s under negotiation
- Total number of SMTA2s (i.e. Category A and B agreements) under review

**Documents or tools produced as part of the operationalization of SMTA2s**

- Number of documents or tools produced as part of the SMTA2 operationalization
- Name of document or tools
- Objective of content
- Date of production